Potenza Therapeutics’ pipeline of oncology products utilizes the body’s own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms that influence tumor immunity. In April 2015, Potenza and Astellas Pharma Inc. announced an exclusive collaboration to develop novel antibodies for immuno-oncology therapy.

Drug discovery activities are conducted by the drug discovery scientists at Potenza, in close collaboration with Astellas Pharma. Once a drug is ready for human clinical use, the global reach of Astellas enables advancement of clinical development activities and commercialization.

The first compound from the collaboration between Potenza and Astellas, PTZ-201 (ASP8374), has entered Phase I testing in patients in the U.S. Click here to learn more about the clinical trial.